#Targetome
CLDN18.2 emerges as a promising PDAC therapeutic target, with monoclonal antibodies, bispecific antibodies, CAR-T cell therapy, and antibody-drug conjugates showing clinical progress.
Details: https://www.maxapress.com/article/doi/10.48130/targetome-0026-0033
#CLDN18.2 #TargetedTherapy